CAR T-Cell Therapy

At 33.6 months' follow-up, patients with standard-risk multiple myeloma had improved progression-free survival outcomes with ciltacabtagene autoleucel vs standard of care.

Phase 1 data show EB103 delivers 100% complete responses at high dose with manageable toxicity, offering a safer, durable option for high-risk B-cell NHL.

FDA lifts Yescarta limits for relapsed primary CNS lymphoma, expanding CAR T access with phase 1 safety data—what to know about neuro risks.

Phase 2 data show varnim-cel delivers 83% responses with mostly mild CRS and minimal neurotoxicity, boosting CAR T access in India.

A real-world ciltacabtagene autoleucel (cilta-cel) study revealed a link between high lymphocyte peaks and failed bridging to parkinsonism and nonrelapse mortality, potentially guiding early intervention.

FDA grants orphan drug designation to CTD402, a promising CAR T therapy for relapsed T-cell leukemia and lymphoma, enhancing treatment accessibility.

Miguel-Angel Perales, MD, spoke with Targeted Oncology® about the problems the CAR T Vision group has identified and the key short-term and long-term steps being taken to expand the accessibility of CAR T-cell therapy.

FDA approves liso-cel, the first CAR T-cell therapy for relapsed marginal zone lymphoma, offering hope for improved patient outcomes.

During a live event, Thomas G. Martin, MD, discussed the importance of controlling disease and avoiding barriers to access so patients with multiple myeloma can receive CAR T-cell therapy.

Axi-cel shows impressive long-term efficacy in treating relapsed/refractory indolent non-Hodgkin lymphoma, with potential curative outcomes for patients.

During a live event, Thomas G. Martin, MD, discussed updated findings from the CARTITUDE-1 trial of cilta-cel and what they signify for patients with no disease progression at 5 years.

In an interview with Targeted Oncology, Frederick L. Locke, MD, discussed how the elimination of the REMS program for CAR T-cell therapy came about and what effects he hopes this will have on patient access.

Community-based CAR T-cell therapy expands access to innovative cancer treatments, improving patient outcomes and reducing hospital stays for patients with blood cancers.

CAR T-cell therapy for DLBCL shows promise in outpatient settings, reducing hospital stays and improving patient quality of life while managing toxicities effectively.

Explore the complexities of CAR T-cell therapy, focusing on noncanonical toxicities like ICAHT and IEC-HS, and their management strategies.

Emerging CAR T-cell therapies, like DuoCAR20.19.22-D95, show promise in overcoming challenges in treating relapsed B-cell malignancies.

Brexu-cel demonstrated efficacy and safety even in patients with B-cell acute lymphoblastic leukemia with central nervous system involvement.

During a live event, Nathan Denlinger, DO, MS, discussed outcomes of the ZUMA-7 trial in diffuse large B-cell lymphoma.

During a live event, Jorge Monge, MD, discussed real-world evidence on the use of CAR T-cell therapy beyond the trial setting in multiple myeloma.

Allogene Therapeutics halts ALLO-647 trial in large B-cell lymphoma after a patient death raises safety concerns, impacting future research.

FDA prioritizes review of liso-cel, a groundbreaking CAR T-cell therapy for relapsed marginal zone lymphoma, promising improved patient outcomes.

FCARH143, a CAR T-cell therapy, delivered a 100% objective response rate in a phase 1 trial in patients with relapsed/refractory multiple myeloma.

Michael Caligiuri, MD, discusses the modulation of natural killer cells to enhance their ability to detect and destroy tumor cells.

During a live event, Matthew Lunning, DO, and participants discussed how identifying primary refractory and early relapsed DLBCL matters for using second-line CAR T-cell therapy.

During a live event, Jorge Monge, MD, discussed short and long-term adverse events associated with CAR T-cell therapy in multiple myeloma.